{"product_id":"global-asset-purchase-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2016-to-2023","title":"Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016 to 2023","description":"\u003cp\u003eGlobal Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016 to 2023\u003c\/p\u003e\n\n\u003cp\u003eThe Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.\u003cbr\u003e\n \u003cbr\u003e\nThe report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.\u003cbr\u003e\n \u003cbr\u003e\nThe focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.\u003cbr\u003e\n \u003cbr\u003e\nCompanies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.\u003cbr\u003e\n \u003cbr\u003e\nThe report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.\u003cbr\u003e\n \u003cbr\u003e\nThe report focuses on four primary types of asset available for purchase:\u003cbr\u003e\n \u003cbr\u003e\nBusiness assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations\u003cbr\u003e\n \u003cbr\u003e\nProduct assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit\u003cbr\u003e\n \u003cbr\u003e\nRoyalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product\u003cbr\u003e\n \u003cbr\u003e\nTechnology asset - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation\u003cbr\u003e\n \u003cbr\u003e\nUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.\u003cbr\u003e\n \u003cbr\u003e\nThis report contains a comprehensive listing of over 950 asset purchase deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.\u003cbr\u003e\n \u003cbr\u003e\nContract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.\u003cbr\u003e\n \u003cbr\u003e\nThe initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.\u003cbr\u003e\n \u003cbr\u003e\nChapter 3 provides an overview of the structure of asset purchase deals. The chapter includes numerous case studies to enable understanding of both pure asset purchase deals and multicomponent deals where asset purchase forms a part.\u003cbr\u003e\n \u003cbr\u003e\nChapter 4 provides a review of the leading asset purchase deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.\u003cbr\u003e\n \u003cbr\u003e\nChapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. \u003cbr\u003e\n \u003cbr\u003e\nChapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.\u003cbr\u003e\n \u003cbr\u003e\nThe appendices to the report includes a comprehensive listing of all asset purchase deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.\u003cbr\u003e\n \u003cbr\u003e\nThe report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J\u0026amp;J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.\u003cbr\u003e\n \u003cbr\u003e\nThe report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2016.\u003cbr\u003e\n \u003cbr\u003e\nIn conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.\u003cbr\u003e\n \u003cbr\u003e\nKey benefits\u003cbr\u003e\n \u003cbr\u003e\nGlobal Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:\u003cbr\u003e\n \u003cbr\u003e\nIn-depth understanding of asset purchase deal trends since 2016\u003cbr\u003e\nAnalysis of the structure of asset purchase agreements with real life case studies\u003cbr\u003e\nComprehensive access to over 950 actual asset purchase deals entered into by the world’s biopharma companies\u003cbr\u003e\nDetailed access to actual asset purchase deals entered into by leading biopharma companies\u003cbr\u003e\nInsight into the terms included in a asset purchase agreement, together with real world clause examples\u003cbr\u003e\nUnderstand the key deal terms companies have agreed in previous deals           \u003cbr\u003e\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\u003cbr\u003e\n \u003cbr\u003e\nReport scope\u003cbr\u003e\n \u003cbr\u003e\nGlobal Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.\u003cbr\u003e\n \u003cbr\u003e\nGlobal Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023 includes:\u003cbr\u003e\n \u003cbr\u003e\nTrends in asset purchase dealmaking in the biopharma industry since 2016\u003cbr\u003e\nAnalysis of asset purchase deal structure with real life case studies\u003cbr\u003e\nAccess to over 950 asset purchase deal records\u003cbr\u003e\nThe leading asset purchase deals by value since 2016\u003cbr\u003e\nMost active asset purchase dealmakers since 2016\u003cbr\u003e\nThe leading asset purchase partnering resources\u003cbr\u003e\n \u003cbr\u003e\nIn Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2023, the available deals are listed by:\u003cbr\u003e\n \u003cbr\u003e\nCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nStage of development at signing\u003cbr\u003e\nTherapeutic area\u003cbr\u003e\nTechnology type\u003cbr\u003e\n \u003cbr\u003e\nEach deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.\u003cbr\u003e\n \u003cbr\u003e\nThe Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2016-2020 report provides comprehensive access to available records for over 950 asset purchase deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:\u003cbr\u003e\n \u003cbr\u003e\nWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"April, 2023 \/ 550 Pages \/ MCW16229160","offer_id":47646922670386,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-asset-purchase-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2016-to-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}